Citations

Clear

1526 citation(s) found for "Sun, Yu".

Akt and CHIP coregulate tau degradation through coordinated interactions
Dickey, Chad A. , Koren, John , Zhang, Yong‐Jie , Xu, Ya-Fei, Jinwal, Umesh K., Birnbaum, Morris J. , Monks, Bobby R., Sun, Mei , Cheng, Jin , Patterson, Cam, Bailey, Rachel M. , Dunmore, Judith, Soresh, Sareh, Leon, Carlos M.M.P., Morgan, Dave, Petrucelli, Leonard , Zhang, Yong-Jie

Mayo Clinic

Proceedings of the National Academy of Sciences | February 21, 2008 | Volume: 105 | Issue: 9 | Pages: 3622-3627

10.1073/pnas.0709180105 | PMID 18292230 Get It

A hallmark of the pathology of Alzheimer's disease is the accumulation of the microtubule-associated protein tau into fibrillar aggregates. Recent studies suggest that they accumulate because cytosolic chaperones fail to clear abnormally phosphorylated tau, preserving a pool of toxic tau intermediates within the neuron. We describe a mechanism for tau clearance involving a major cellular kinase, Akt. During stress, Akt is ubiquitinated and degraded by the tau ubiquitin ligase CHIP, and this largely depends on the Hsp90 complex. Akt also prevents CHIP-induced tau ubiquitination and its subsequent degradation, either by regulating the Hsp90/CHIP complex directly or by competing as a client protein with tau for binding. Akt levels tightly regulate the expression of CHIP, such that, as Akt levels are suppressed, CHIP levels also decrease, suggesting a potential stress response feedback mechanism between ligase and kinase activity. We also show that Akt and the microtubule affinity-regulating kinase 2 (PAR1/MARK2), a known tau kinase, interact directly. Akt enhances the activity of PAR1 to promote tau hyperphosphorylation at S262/S356, a tau species that is not recognized by the CHIP/Hsp90 complex. Moreover, Akt1 knockout mice have reduced levels of tau phosphorylated at PAR1/MARK2 consensus sites. Hence, Akt serves as a major regulator of tau biology by manipulating both tau kinases and protein quality control, providing a link to several common pathways that have demonstrated dysfunction in Alzheimer's disease.
Non-Overlapping and Non–Cell-Type–Specific Gene Expression Signatures Predict Lung Cancer Survival
Sun, Zhifu , Wigle, Dennis A. , Yang, Ping , Sun, Zhifu

Mayo Clinic

Journal of Clinical Oncology | February 16, 2008 | Volume: 26 | Issue: 6 | Pages: 877-883

10.1200/jco.2007.13.1516 | PMID 18281660 Get It

Purpose Gene expression profiling for outcome prediction of non–small-cell lung cancer (NSCLC) remains clouded by heterogeneous and unvalidated results. This study applied multivariate approaches to identify and evaluate value-added gene expression signatures in two types of NSCLC. Materials and Methods Two NSCLC oligonucleotide microarray data sets of adenocarcinoma and squamous cell carcinoma were used as training sets to select prognostic genes independent of conventional predictors. The top 50 genes from each set were used to predict the outcomes of two independent validation data sets of 84 and 91 NSCLC cases. Results Adenocarcinomas with the 50-gene signature from adenocarcinoma in both validation data sets had a 2.4-fold (95% CI, 1.3 to 4.4 and 1.0 to 5.8) increased mortality after adjustment for conventional predictors. Squamous cell carcinoma with this high-risk signature had an adjusted risk of 1.1 (95% CI, 0.4 to 3.2) in one data set and 2.5 (95% CI, 1.1 to 5.8) in another consisting of stage I tumors. Adenocarcinoma with the 50-gene signature from squamous cell carcinoma had an elevated risk of 3.5 (95% CI, 1.4 to 9.0) after adjustment for conventional predictors. Squamous cell carcinoma with this high risk signature had an adjusted risk of 1.8 (95% CI, 0.7 to 4.6). Despite the little overlap in individual genes, the two gene signatures had significant functional connectedness in molecular pathways. Conclusion Two non-overlapping but functionally related gene expression signatures provide consistently improved survival prediction for NSCLC regardless of histologic cell type. Multiple sets of genes may exist for NSCLC with predictive value, but ones with independent predictive value beyond clinical predictors will be required for clinical translation.
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment
Fleisher, Adam , Sun, Shichang , Ward, Chad, Gamst, Anthony, Petersen, Ronald C. , Jack, Clifford R. , Aisen, Paul , Thal, L. J., Taylor, Catherine Louise , Jack, Clifford R

Mayo Clinic

Neurology | January 14, 2008 | Volume: 70 | Issue: 3 | Pages: 191-199

10.1212/01.wnl.0000287091.57376.65 | PMID 18195264 Get It

Secreted Frizzled-Related Protein 1 Loss Contributes to Tumor Phenotype of Clear Cell Renal Cell Carcinoma
Zou, Hongzhi , Kreinest, Pamela, Childs, April C., Belmonte, Leandra S., LeGrand, Shauna N., Wu, Kevin J. , Luxon, Bruce A. , Sinha, Mala, Parker, Alexander S. , Sun, L-Z, Ahlquist, David A. , Wood, Christopher G. , Copland, John A. , Gumz, Michelle L.

Mayo Clinic

Clinical Cancer Research | August 15, 2007 | Volume: 13 | Issue: 16 | Pages: 4740-4749

10.1158/1078-0432.ccr-07-0143 | PMID 17699851 Get It

Abstract Purpose: Incidence and mortality rates for renal cell carcinoma (RCC) have been rising for decades. Unfortunately, the molecular events that support RCC carcinogenesis remain poorly understood. In an effort to gain a better understanding of signaling events in clear cell RCC (cRCC), we investigated the antitumor activity of secreted frizzled-related protein 1 (sFRP1), a negative regulator of Wnt signaling. Experimental Design: Genomic profiling of cRCC tumors and patient-matched normal tissues was done and confirmed using quantitative PCR and immunohistochemistry. Methylation-specific PCR was done on patient samples to evaluate the mechanism responsible for sFRP1 loss. sFRP1 expression was restored in cRCC cells and the effects on tumor phenotype were characterized. Results: Genomic profiling, quantitative PCR, and immunohistochemistry indicated that loss of sFRP1 occurred in cRCC and papillary RCC patient tissues. Twelve Wnt-regulated genes were up-regulated in cRCC tissues, including c-myc and cyclin D1, potentiators of cell proliferation and survival. Methylation of the sFRP1 gene was one mechanism identified for attenuation of sFRP1 mRNA. Stable reexpression of sFRP1 in cRCC cells resulted in decreased expression of Wnt target genes, decreased growth in cell culture, inhibition of anchorage-independent growth, and decreased tumor growth in athymic nude mice. Conclusions: To our knowledge, this is the first report to show that stable restoration of sFRP1 expression in cRCC cells attenuates the cRCC tumor phenotype. Our data support a role for sFRP1 as a tumor suppressor in cRCC and that perhaps loss of sFRP1 is an early, aberrant molecular event in renal cell carcinogenesis.
Gene-Expression Profiling in Lung Cancer: Still Early Days
Sun, Zhifu , Yang, Ping , Sun, Zhifu

Mayo Clinic

Pharmacogenomics | February 7, 2007 | Volume: 8 | Issue: 2 | Pages: 129-132

10.2217/14622416.8.2.129 | PMID 17286534 Get It

Images in vascular medicine
Tse, Tak-Sun, Cooper, Leslie T.

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 6 | Issue: 4 | Pages: 267-268

10.1177/1358836x0100600412 | PMID 11958395 Get It

Gene Expression Profiling on Lung Cancer Outcome Prediction: Present Clinical Value and Future Premise
Sun, Zhifu , Yang, Ping , Sun, Zhifu

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 21, 2006 | Volume: 15 | Issue: 11 | Pages: 2063-2068

10.1158/1055-9965.epi-06-0505 | PMID 17119029 Get It

Abstract DNA microarray has been widely used in cancer research to better predict clinical outcomes and potentially improve patient management. The new approach provides accurate tumor classification and outcome predictions, such as tumor stage, metastatic status, and patient survival, and offers some hope for individualized medicine. However, growing evidence suggests that gene-based prediction is not stable and little is known about the prediction power of gene expression profiles compared with well-known clinical and pathologic predictors. This review summarized up-to-date publications in microarray-based lung cancer clinical outcome prediction and conducted secondary analyses for those with sufficient sample sizes and associated clinical information. Among the most commonly used analytic approaches, unsupervised clustering mainly recaptures tumor histology and provides variable degrees of prediction for tumor stage, lymph node status, or survival. Overall, most studies lack an independent validation. Supervised learning and testing generally offer a better prediction. Noted is that when conventional predictors of age, gender, stage, cell type, and tumor grade are considered collectively, the predictive advantage of the gene expression profiles diminishes. We conclude that outcome prediction from gene expression signatures selected by current analytic approaches can be mostly explained by well-known conventional predictors, particularly histologic subtype and grade of differentiation. A strategy for establishing independent or more accurate signatures is commented. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2063–8)
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Walker, Douglas G. , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine, Schmechel, Donald E., Alexander, Gene E. , Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | October 31, 2006 | Volume: 28 | Issue: 3 | Pages: 311-322

10.1152/physiolgenomics.00208.2006 | PMID 17077275 Get It

In this article, we have characterized and compared gene expression profiles from laser capture microdissected neurons in six functionally and anatomically distinct regions from clinically and histopathologically normal aged human brains. These regions, which are also known to be differentially vulnerable to the histopathological and metabolic features of Alzheimer’s disease (AD), include the entorhinal cortex and hippocampus (limbic and paralimbic areas vulnerable to early neurofibrillary tangle pathology in AD), posterior cingulate cortex (a paralimbic area vulnerable to early metabolic abnormalities in AD), temporal and prefrontal cortex (unimodal and heteromodal sensory association areas vulnerable to early neuritic plaque pathology in AD), and primary visual cortex (a primary sensory area relatively spared in early AD). These neuronal profiles will provide valuable reference information for future studies of the brain, in normal aging, AD and other neurological and psychiatric disorders.
The Impact of Overt and Subclinical Hyperthyroidism on Skeletal Muscle
Brennan, Michael , Powell, Claudia, Kaufman, Kenton R. , Sun, Pi Chang, Bahn, Rebecca S. , Nair, K. Sreekumaran , Kaufman, Kenton R

Mayo Clinic

Thyroid | April 28, 2006 | Volume: 16 | Issue: 4 | Pages: 375-380

10.1089/thy.2006.16.375 | PMID 16646684 Get It

A Prospective, Case-control Study of Tobacco Dependence in Thromboangiitis Obliterans (Buerger’s Disease)
Cooper, Leslie T. , Henderson, Stavonnie S., Offord, Kenneth P., Tse, Tak Sun, Holmes, David R. , Hurt, R. Douglas , Ballman, Karla V. , Cooper, Leslie T

Mayo Clinic

Angiology | March 31, 2006 | Volume: 57 | Issue: 1 | Pages: 73-78

10.1177/000331970605700110 | PMID 16444459 Get It

Thromboangiitis obliterans (TAO) is often cited as an extreme phenotype of vasculopathy and tobacco dependence. Although tobacco exposure is essential to progression of arterial ischemia in TAO, expert opinion differs regarding the degree of tobacco dependence in this population. The authors designed a prospective, case-control study to test the hypothesis that subjects with TAO have a greater degree of tobacco dependence than control subjects with coronary atherosclerosis (coronary artery disease [CAD]) do. Subjects with TAO (n=218, confirmed by angiography, biopsy, or noninvasive arterial testing) or CAD (n=343, diagnosed by coronary angiography) were mailed a standardized questionnaire regarding tobacco use, to which 103 and 273 responded, respectively. The degree of tobacco dependence in each group was ascertained by several methods, including the Fagerström Test for Nicotine Dependence Questionnaire. The TAO group was younger at index date (year of first diagnosis for TAO patients, year of percutaneous transluminal coronary angioplasty [PTCA] for CAD patients) (TAO 37.6 ±9.0 vs CAD 43.3 ±4.9 yr, p<0.0001), but the groups did not differ in age at first tobacco exposure (TAO 16.7 ±3.1 vs CAD 17.3 ±4.2 yr, p=0.67), current tobacco use at time of survey (TAO 54% vs CAD 46%, p=0.17), or Fagerström score (TAO 4.7 ±2.3 vs CAD 5.1 ±2.3, p=0.24). Kaplan-Meier curves showed no significant difference in time to stopping tobacco use after first diagnosis (p=0.076). TAO subjects smoked fewer cigarettes per day than CAD subjects (TAO 22.3 ±10.7 vs CAD 27.7 ±15.3 cigarettes/day, p=0.003). Among current smokers (n=170), TAO subjects also smoked fewer cigarettes/day (20.2 ±8.2 vs 24.6 ±12.7, p=0.03), and were more likely to have made a serious attempt to stop (97% vs 90%, p=0.03). In contrast to case reports of extreme tobacco dependence in the TAO population, the degree of tobacco dependence in subjects with TAO is similar to that in subjects with CAD.